Aprea Therapeutics' WEE1 Inhibitor APR-1051 Shows Early Activity, Good Tolerability in Updated Phase 1 ASCO Data
APRE sits 66% above its 52-week low of $0.548 on light trading volume (0.3× avg).
Summary
Aprea Therapeutics presented updated positive Phase 1 data for its WEE1 inhibitor APR-1051 at ASCO 2026, demonstrating early monotherapy activity and manageable tolerability in advanced solid tumors. The data includes two partial responses in endometrial cancer patients and stable disease in six others, reinforcing the drug's potential. This builds on the initial positive clinical data for APR-1051 announced in an 8-K on March 16th. For this clinical-stage company, these results are crucial for advancing its lead candidate. Dose escalation and expansion into additional cancer types are expected to complete in Q2 2027.
At the time of this announcement, APRE was trading at $0.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.1M. The 52-week trading range was $0.55 to $2.22. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.